Anterogen.Co.,Ltd. Logo

Anterogen.Co.,Ltd.

065660.KQ

(0.0)
Stock Price

14.400,00 KRW

-2.05% ROA

-1.86% ROE

-61.82x PER

Market Cap.

143.051.139.000,00 KRW

0% DER

0% Yield

-34.75% NPM

Anterogen.Co.,Ltd. Stock Analysis

Anterogen.Co.,Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Anterogen.Co.,Ltd. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Anterogen.Co.,Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Anterogen.Co.,Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Hold

Anterogen.Co.,Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Anterogen.Co.,Ltd. Revenue
Year Revenue Growth
2014 1.834.279.960
2015 3.532.247.770 48.07%
2016 4.896.068.260 27.86%
2017 5.357.319.240 8.61%
2018 3.607.167.170 -48.52%
2019 4.147.568.020 13.03%
2020 4.151.233.470 0.09%
2021 8.121.552.700 48.89%
2022 6.591.010.790 -23.22%
2023 6.500.249.535 -1.4%
2024 6.839.449.220 4.96%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Anterogen.Co.,Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2014 1.142.533.740
2015 907.745.860 -25.86%
2016 1.545.372.900 41.26%
2017 1.304.972.690 -18.42%
2018 1.870.012.490 30.22%
2019 2.532.898.570 26.17%
2020 4.006.693.720 36.78%
2021 4.194.427.480 4.48%
2022 4.658.232.550 9.96%
2023 5.383.561.967 13.47%
2024 3.743.172.648 -43.82%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Anterogen.Co.,Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2014 178.980.180
2015 142.401.520 -25.69%
2016 198.239.070 28.17%
2017 196.385.390 -0.94%
2018 143.462.410 -36.89%
2019 154.991.920 7.44%
2020 117.717.680 -31.66%
2021 227.178.370 48.18%
2022 804.505.540 71.76%
2023 209.615.770 -283.8%
2024 6.173.132.000 96.6%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Anterogen.Co.,Ltd. EBITDA
Year EBITDA Growth
2014 -1.323.039.630
2015 171.224.140 872.69%
2016 458.601.300 62.66%
2017 550.809.720 16.74%
2018 -1.044.569.180 152.73%
2019 -1.153.778.780 9.47%
2020 -1.912.267.740 39.66%
2021 -1.307.471.320 -46.26%
2022 -2.233.410.400 41.46%
2023 -4.226.541.470 47.16%
2024 -3.069.195.280 -37.71%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Anterogen.Co.,Ltd. Gross Profit
Year Gross Profit Growth
2014 1.037.805.280
2015 2.351.986.960 55.88%
2016 3.502.416.390 32.85%
2017 3.251.225.040 -7.73%
2018 1.686.986.250 -92.72%
2019 1.660.727.130 -1.58%
2020 1.742.145.150 4.67%
2021 3.872.163.260 55.01%
2022 2.616.411.190 -48%
2023 2.213.441.435 -18.21%
2024 2.346.489.088 5.67%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Anterogen.Co.,Ltd. Net Profit
Year Net Profit Growth
2014 -1.415.653.390
2015 -58.309.090 -2327.84%
2016 371.659.590 115.69%
2017 446.737.570 16.81%
2018 -961.759.730 146.45%
2019 -4.049.844.880 76.25%
2020 -4.375.063.260 7.43%
2021 -553.984.070 -689.75%
2022 -6.837.097.540 91.9%
2023 -2.840.849.743 -140.67%
2024 -2.071.845.384 -37.12%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Anterogen.Co.,Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2014 -218
2015 -9 -2322.22%
2016 50 118%
2017 57 12.28%
2018 -114 150%
2019 -470 75.69%
2020 -481 2.49%
2021 -59 -715.25%
2022 -706 91.63%
2023 -292 -142.27%
2024 -213 -37.26%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Anterogen.Co.,Ltd. Free Cashflow
Year Free Cashflow Growth
2014 -1.772.460.020
2015 185.491.730 1055.55%
2016 -6.189.716.330 103%
2017 -980.509.860 -531.28%
2018 -6.516.905.660 84.95%
2019 -4.666.756.660 -39.65%
2020 -10.151.314.220 54.03%
2021 -6.584.971.830 -54.16%
2022 -3.456.182.030 -90.53%
2023 -2.191.497.687 -57.71%
2024 497.311.241 540.67%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Anterogen.Co.,Ltd. Operating Cashflow
Year Operating Cashflow Growth
2014 -1.010.252.750
2015 844.493.920 219.63%
2016 -130.648.830 746.38%
2017 379.205.990 134.45%
2018 -1.504.760.530 125.2%
2019 -1.648.844.500 8.74%
2020 -4.414.918.170 62.65%
2021 -3.045.351.650 -44.97%
2022 -1.975.372.510 -54.17%
2023 -1.988.220.126 0.65%
2024 595.768.732 433.72%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Anterogen.Co.,Ltd. Capital Expenditure
Year Capital Expenditure Growth
2014 762.207.270
2015 659.002.190 -15.66%
2016 6.059.067.500 89.12%
2017 1.359.715.850 -345.61%
2018 5.012.145.130 72.87%
2019 3.017.912.160 -66.08%
2020 5.736.396.050 47.39%
2021 3.539.620.180 -62.06%
2022 1.480.809.520 -139.03%
2023 203.277.561 -628.47%
2024 98.457.491 -106.46%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Anterogen.Co.,Ltd. Equity
Year Equity Growth
2015 16.639.306.730
2016 34.023.830.568 51.1%
2017 46.606.325.737 27%
2018 56.072.728.501 16.88%
2019 68.393.648.701 18.01%
2020 81.067.066.520 15.63%
2021 116.866.595.777 30.63%
2022 106.791.384.883 -9.43%
2023 129.444.937.057 17.5%
2024 114.746.613.811 -12.81%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Anterogen.Co.,Ltd. Assets
Year Assets Growth
2015 18.487.653.142
2016 35.427.915.199 47.82%
2017 58.136.238.240 39.06%
2018 101.441.140.661 42.69%
2019 84.593.764.521 -19.92%
2020 94.204.109.431 10.2%
2021 136.700.767.700 31.09%
2022 124.132.713.131 -10.12%
2023 149.431.676.947 16.93%
2024 118.387.796.177 -26.22%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Anterogen.Co.,Ltd. Liabilities
Year Liabilities Growth
2015 1.848.346.412
2016 1.404.084.630 -31.64%
2017 11.529.912.503 87.82%
2018 45.368.412.160 74.59%
2019 16.200.115.820 -180.05%
2020 13.137.042.911 -23.32%
2021 19.834.171.923 33.77%
2022 17.341.328.248 -14.38%
2023 19.986.739.890 13.24%
2024 3.641.182.366 -448.91%

Anterogen.Co.,Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
684.25
Net Income per Share
-237.78
Price to Earning Ratio
-61.82x
Price To Sales Ratio
21.48x
POCF Ratio
-15800.43
PFCF Ratio
-451.61
Price to Book Ratio
1.25
EV to Sales
21.25
EV Over EBITDA
-51.86
EV to Operating CashFlow
-15626.33
EV to FreeCashFlow
-446.63
Earnings Yield
-0.02
FreeCashFlow Yield
-0
Market Cap
143,05 Bil.
Enterprise Value
141,48 Bil.
Graham Number
7942.59
Graham NetNet
4157.39

Income Statement Metrics

Net Income per Share
-237.78
Income Quality
0
ROE
-0.02
Return On Assets
-0.02
Return On Capital Employed
-0.03
Net Income per EBT
1
EBT Per Ebit
0.59
Ebit per Revenue
-0.59
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0.26
Research & Developement to Revenue
0.62
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.39
Operating Profit Margin
-0.59
Pretax Profit Margin
-0.35
Net Profit Margin
-0.35

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.93
Free CashFlow per Share
-32.55
Capex to Operating CashFlow
-33.99
Capex to Revenue
0.05
Capex to Depreciation
0.4
Return on Invested Capital
-0.03
Return on Tangible Assets
-0.02
Days Sales Outstanding
221.73
Days Payables Outstanding
89.45
Days of Inventory on Hand
91.53
Receivables Turnover
1.65
Payables Turnover
4.08
Inventory Turnover
3.99
Capex per Share
31.62

Balance Sheet

Cash per Share
4.167,83
Book Value per Share
11.791,41
Tangible Book Value per Share
11204.07
Shareholders Equity per Share
11791.41
Interest Debt per Share
95.47
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.58
Current Ratio
45.24
Tangible Asset Value
109,03 Bil.
Net Current Asset Value
42,23 Bil.
Invested Capital
72981575060
Working Capital
44,86 Bil.
Intangibles to Total Assets
0.05
Average Receivables
4,10 Bil.
Average Payables
0,76 Bil.
Average Inventory
1243322266
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Anterogen.Co.,Ltd. Dividends
Year Dividends Growth

Anterogen.Co.,Ltd. Profile

About Anterogen.Co.,Ltd.

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as human stem cell conditioned media, a cosmetic raw material. In addition, the company offers cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.

CEO
Seong-Gu Lee
Employee
35
Address
Namsung Plaza
Seoul, 08589

Anterogen.Co.,Ltd. Executives & BODs

Anterogen.Co.,Ltd. Executives & BODs
# Name Age
1 Seong-Gu Lee
Chief Executive Officer
70

Anterogen.Co.,Ltd. Competitors

Daewon Cable. Co., Ltd. Logo
Daewon Cable. Co., Ltd.

006340.KS

(2.0)
Namsun Aluminum Co., Ltd. Logo
Namsun Aluminum Co., Ltd.

008350.KS

(2.0)
Korea Line Corporation Logo
Korea Line Corporation

005880.KS

(2.0)